Guo Ji Jin Rong Bao·2026-02-05 02:29Group 1 - The acquisition of Jiatang by Tongrentang Group aims to create a complete closed-loop pharmaceutical industry chain covering herbal planting, drug production, terminal distribution, and medical services, but its effectiveness in alleviating the "private label" pain remains to be seen [1][7] - On February 3, Jiatang announced that its shareholders, Everbright Industrial and Everbright Health, signed a share transfer agreement with Tongrentang Group, transferring a total of 83.05 million shares for 1.461 billion yuan [3] - Following the transaction, Tongrentang Group will become the controlling shareholder of Jiatang with a 28.48% stake, and the actual controller will change to the State-owned Assets Supervision and Administration Commission of Beijing [3][4] Group 2 - Jiatang has faced financial pressure, with revenue figures from 2020 to 2024 showing a decline in net profit, particularly a drop to 161 million yuan in 2024, marking a ten-year low [5] - For the first three quarters of 2025, Jiatang reported a revenue of 14.46 billion yuan, a year-on-year decrease of 21.8%, and a net profit of 141 million yuan, down 38.81% year-on-year [6] - Tongrentang, founded in 1669, currently has multiple listed companies and is actively pursuing the listing of Tongrentang Medical and Health, which could enhance its capital presence [7] Group 3 - The merger is viewed as a "strong union," combining Tongrentang's brand strength and product resources with Jiatang's extensive distribution network, potentially allowing Jiatang to return to its core pharmaceutical operations [7] - Tongrentang has recently faced a trust crisis due to a product quality issue, which has negatively impacted its stock price and overall performance, with a revenue decline of 3.70% and a net profit drop of 12.78% in the first three quarters of 2025 [8]